Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Walker & Dunlop reported a net loss of $37.3 million for the third quarter of 2026, a significant decline from a $33.5 million profit in the prior year, primarily driven by a surge in indemnified and repurchased loan expenses. Total revenues decreased by 11.6% to $298.4 million for the quarter, while total assets fell to $4.26 billion as of September 30, 2026.
Cognition Therapeutics reported a decrease in cash and cash equivalents to $30.8 million as of September 30, 2026, compared to $36.8 million at year-end 2025. The company's accumulated deficit grew to $211.3 million, reflecting ongoing clinical development costs for its lead product candidate, zervimesine (CT1812).
Targa Resources reported Q3 2026 net income of $658 million and record adjusted EBITDA of $1.5 billion, driven by record Permian inlet and NGL fractionation volumes. The company raised its full-year 2026 adjusted EBITDA guidance to at least $6.0 billion and announced plans for a 20% dividend increase in 2027.
Uranium Energy Wins Contract from two prominent U.S. nuclear utilities
Uranium Energy Corp's subsidiary entered into definitive long-term sales agreements with two U.S. nuclear utilities to deliver 1.1 million pounds of uranium concentrates over a six-year period. The contracts utilize an unhedged strategy where deliveries (scheduled from 2027 through 2032) will be priced at prevailing spot market prices rather than fixed rates.
Ducommun Incorporated reported a restatement of prior consolidated financial statements and identified a material weakness in internal control over financial reporting. The company's balance sheet as of October 3, 2026, shows $39.2 million in cash and $163.2 million in net accounts receivable, with total shares outstanding of 15,124,087 as of October 29, 2026.
Ingredion reported third quarter 2026 results with reported diluted EPS of $2.23 and adjusted diluted EPS of $2.28, both down from the prior year. The company lowered its full-year 2026 guidance, citing a slower-than-anticipated recovery at its Argo facility and pressure from higher input costs and soft consumer demand.
Term
Q3 2026
“Our third quarter results fell short of our expectations, largely due to Argo’s slower than anticipated financial recovery, with incremental pressure from higher input costs and consumer softness.”
Jim Zallie, chairman, president and CEO
“As a result, we are lowering our full-year outlook, primarily to reflect the slower earnings recovery in Food & Industrial Ingredients—U.S./CAN, along with the impacts of higher input costs and softer demand.”
Ducommun Incorporated reported record third-quarter 2026 revenue of $227.0 million and an all-time high gross margin of 28.9%. The company achieved a record backlog (RPO) of $1.3 billion, driven by strong commercial aerospace growth and a defense book-to-bill ratio of 2.2x.
Term
Q3 2026
“Another excellent quarter for Ducommun in 2026. With record revenue and gross margins in Q3, we continued to make great progress towards accomplishing our VISION 2027 goals and positioning ourselves for our new VISION 2032 Plan which was communicated in September.”
Stephen G. Oswald, chairman, president and chief executive officer
“Gross margin expansion is an important story for DCO and its investors and was once again very strong in the quarter expanding 140 bps year-over-year to another all-time record of 28.9%.”
Stephen G. Oswald, chairman, president and chief executive officer
Enovis reported Q3 2026 net sales of $559 million, representing 5% organic growth, driven by a 6% increase in its Reconstructive segment. The company raised its full-year 2026 guidance for adjusted EBITDA and adjusted EPS while announcing a new $200 million share repurchase authorization.
Term
Q3 2026
“Our third-quarter results reflect continued progress against our innovation-led strategy and the benefits of executing with greater alignment, accountability, and discipline.”
Damien McDonald, Chief Executive Officer of Enovis
“Growth was consistent with our expectations for the quarter, with continued share gains in Recon and steady performance in Prevention & Recovery.”
Damien McDonald, Chief Executive Officer of Enovis
Privia Health Group reported strong third quarter 2026 results with revenue increasing 13.2% year-over-year to $657.0 million and net income nearly doubling to $13.5 million. The company raised its full-year 2026 guidance across all key financial metrics and announced the acquisition of American Choice Healthcare's MSSP business to expand its value-based care footprint.
Prestige Consumer Healthcare reported total revenues of $336.3 million for the quarter ended September 30, 2026, up from $274.1 million in the prior year, though net income decreased to $25.3 million due to higher interest expenses and acquisition-related costs. The company significantly expanded its balance sheet through a $1.19 billion acquisition, funded by new term loans and senior notes.
Oscar Health reported Q3 2026 financial results with total revenue of $5.14 billion, a significant increase from $2.99 billion in the prior year. The company achieved net income of $167.3 million compared to a net loss in Q3 2025 and raised its full-year 2026 earnings from operations outlook to a range of $850 million to $950 million.
Term
Q3 2026
“Oscar Health is on track to deliver the strongest year of financial performance in our history, and we are raising our earnings from operations outlook for a third time. The ACA is the foundation of a rapidly-developing individual market in America, and Oscar Health is built to lead it. Our disciplined pricing, consumer-led products, and technology-powered approach are driving stronger economics and position us to grow market share and expand margin in 2027.”
BeOne Medicines Ltd. reported significant growth for the quarter ended September 30, 2026, with total revenues increasing to $1.89 billion from $1.41 billion in the prior year. Net income rose substantially to $384.7 million, or $3.28 per diluted ADS, driven by strong product sales and improved operating leverage despite increased R&D and SG&A spending.
DataMeds AI Deal Termination with EOS Technology Holdings, Inc.
DataMEDS AI, Inc. has terminated its Second Amended and Restated Letter of Intent (LOI) with multiple parties including EOS Technology Holdings, Scilex, and Datavault AI. The LOI contemplated the acquisition of intellectual property assets and a controlling interest in Tollo Health in exchange for common stock, but was cancelled due to market conditions. The company stated that no shares will be issued and no fees are owed as a result of the termination.
GigaCloud Technology Inc. reported its financial results for the quarter ended September 30, 2026, showing a total of 35,624,024 ordinary shares outstanding as of October 31, 2026. The company continues to operate its GigaCloud Marketplace, focusing on both 1P and 3P seller GMV growth across global e-commerce platforms.
Arhaus, Inc. reported net revenue of $1.07 billion for the nine months ended September 30, 2026, a 5.2% increase year-over-year, though net income slightly decreased to $49.7 million from $52.2 million. The company maintained a strong cash position of $318 million and saw a significant increase in client deposits to $325 million.
Haemonetics Corp reported net revenues of $357.8 million for the quarter ended September 26, 2026, a 9.3% increase compared to the prior year. Net income rose to $46.3 million, driven by higher gross profits and the absence of intangible asset impairments that occurred in the previous year's quarter.
National Grid reported a 55% increase in statutory operating profit to £2,359 million for the half year ended September 30, 2026, driven by record capital investment of £6.7 billion. The company raised its 2026/27 underlying EPS guidance to an expected 15-16% increase from the 2025/26 baseline, reflecting the transition to the RIIO-T3 price control and continued US rate base growth.
Lincoln National Corp reported Q3 2026 net income of $1.3 billion, or $6.77 per diluted share, and adjusted operating income of $339 million. The company resumed share repurchases with $50 million of common stock and retired $437 million of preferred stock, while holding company liquidity increased to $1.0 billion.
Term
Q3 2026
“Our increasingly diversified earnings base continues to support Lincoln’s overall performance. Life Insurance and Retirement Plan Services were highlights of the quarter, both delivering strong year-over-year earnings growth and reinforcing the resilience of our business mix.”
Ellen Cooper, Chairman, President and CEO
“Closing our reinsurance transaction with Talcott in October marked one of the final milestones of the plan we laid out in 2023, further de-risking our balance sheet. With significantly improved financial flexibility, we resumed share repurchases, an important step in expanding durable capital returns.”
Eve Holding reported a net loss of $58.1 million for the third quarter of 2026, driven by $48.3 million in R&D expenses as it continues to develop its eVTOL aircraft. The company ended the quarter with $356 million in cash and total liquidity of $470.4 million, which management believes is sufficient to fund operations through 2028.
MidCap Financial Investment Corp reported its Q3 2026 operational results, highlighting a net asset value (NAV) of $12.86 per share and net investment income of $0.34 per share. The company also noted its pending acquisition by Ares Capital Corporation (ARCC) and declared a quarterly dividend of $0.31 per share.
Cognition Therapeutics received a deficiency notice from Nasdaq on November 3, 2026, because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has until May 3, 2027, to regain compliance by having its stock price close at or above $1.00 for at least 10 consecutive business days.
Counterparty
Nasdaq
Term
180 days
“The work we conducted with the Office of Neuroscience at the FDA during 2026 culminated in the development of a trial protocol for a planned registrational study of zervimesine (CT1812) in people with dementia with Lewy bodies (DLB). We are now evaluating our plans for manufacturing, site selection, and patient recruitment.”
Lisa Ricciardi, Cognition’s president and CEO
“At the same time, we are working with our collaborators at the Alzheimer’s Clinical Trial Consortium (ACTC) to prepare for the conclusion of the Phase 2 START Study in people with MCI and early Alzheimer’s disease. Top-line results from START are anticipated in the second half of 2027 and will inform our plans for zervimesine in Alzheimer’s disease.”
GigaCloud Technology reported record third quarter 2026 results, with total revenues increasing 27.4% year-over-year to $423.6 million. Net income rose 36.0% to $50.6 million, driven by strong growth in Marketplace GMV and a 22.3% increase in active 3P sellers.
Term
Q3 2026
“Periods of market uncertainty underscore the importance of a clear long-term vision and consistent execution. Our growth reflects a long-term strategy built around multiple drivers, including new product development, geographic expansion into markets such as Europe, broader sales channels through partnerships and strategic M&A, and new models that better serve our customers. Growth is not built in a single quarter – it is built over time”
Citizens Financial Services reported net income of $11.9 million for the quarter ended September 30, 2026, up from $10.0 million in the prior year. The company maintained a strong investment portfolio with $477.6 million in available-for-sale securities, though it recorded $33.4 million in gross unrealized losses due to market conditions.
BeOne Medicines reported third quarter 2026 total global revenues of $1.9 billion, a 34% increase year-over-year, driven by strong sales of its BTK inhibitor BRUKINSA. The company achieved GAAP net income of $384.7 million and raised its full-year 2026 revenue guidance to a range of $6.9 billion to $7.0 billion.
Term
3 months
“Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI.”
Primo Brands reported Q3 2026 net sales of $1.82 billion, a 3.1% increase driven by premium brands and regional spring water. The company also announced a new $300 million share repurchase program and updated its full-year 2026 outlook, expecting net sales at the midpoint and Adjusted EBITDA at the lower end of previous guidance.
Term
Q3 2026
“Our third quarter results demonstrate solid top-line momentum and improving execution across the business. This led to Direct Delivery growth ahead of our expectations, broad-based Retail sales growth, and category dollar share gains.”
Eric Foss, Chairman and Chief Executive Officer
“Our new $300 million share repurchase program provides another avenue to continue to return capital to shareholders, while maintaining focus on investing for long-term growth and reducing net leverage.”
Novelis reported second quarter fiscal year 2027 results with net sales increasing 25% year-over-year to $5.9 billion, driven by higher aluminum prices. Net income rose 29% to $210 million, supported by insurance recoveries from the 2025 Oswego fires and favorable metal benefits.
Term
Q2 2027
“We delivered strong quarterly results, reflecting disciplined execution, resilient demand and favorable market conditions. We are excited about the opportunities ahead as Bay Minette moves closer to commercial production, increasing our ability to serve the undersupplied North American market.”
Steve Fisher, president and CEO, Novelis Inc.
“As Bay Minette transitions from construction to start-up, reduced capital spending, continued cost discipline and solid underlying business conditions are expected to drive a return to positive free cash flow and mark the beginning of a deleveraging cycle toward the end of this fiscal year.”
Dev Ahuja, executive vice president and CFO, Novelis Inc.
Celsius Holdings reported record third-quarter revenue of $847.2 million, a 17% increase year-over-year, driven by strong performance from the Alani Nu brand. Net income rose significantly to $127.0 million compared to a loss in the prior year, though gross margins compressed by 450 basis points to 46.8%.
Term
Q3 2026
“We delivered record quarterly revenue in the third quarter of 2026, reflecting the strength of our scaled, multi-brand Modern Energy platform and continued execution of our total energy portfolio strategy.”
John Fieldly, Chairman and CEO of Celsius Holdings
Arhaus reported third quarter 2026 net revenue of $368 million, a 6.8% increase year-over-year, driven by strong client demand and 13.9% growth in comparable written sales. Net income decreased 36% to $8 million as the company continued investments in its showroom network, including the relocation of its second-largest showroom in Charlotte, North Carolina.
Term
Q3 2026
“For 40 years, Arhaus has been defined by exceptional craftsmanship, timeless design, and distinctive products. Our continued investment in compelling new collections and expanded customization is resonating with clients, as reflected in third-quarter Comparable Written Sales growth of 13.9%.”
John Reed, Co-Founder and Chief Executive Officer
“We are pleased with our third-quarter performance, which reflects strong client demand, disciplined execution, and continued progress across our strategic priorities. Our investments in our people, infrastructure, and technology are strengthening our foundation and positioning Arhaus for sustainable, profitable long-term growth.”
Haemonetics reported second quarter fiscal 2027 revenue of $358 million, a 9% increase driven by strong performance in its Apheresis business. The company achieved GAAP diluted EPS of $1.00 and adjusted diluted EPS of $1.35, benefiting from gross margin expansion and the transformation of its product portfolio toward higher-margin offerings.
Term
Q2 2027
“Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value.”
InMed Pharmaceuticals Inc. (renamed Mentari Therapeutics, Inc.) completed a 1-for-10 reverse stock split (consolidation) of its common shares effective November 4, 2026. The split reduced the outstanding share count from approximately 5.49 million to 0.55 million shares to facilitate its pending merger and reorganization with Mentari Therapeutics, Inc. (Delaware).